Iovance第三季度财报：为何在市场反应下我仍重申买入评级（纳斯达克：IOVA）
· seekingalpha.com
Iovance Biotherapeutics, Inc. 发布了强劲的第三季度业绩，营收同比增长约80%，毛利率提升至60%。阅读了解为何IOVA股票值得买入。
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...